Epcoritamab

Therapeutic indications

Epcoritamab is indicated for:

Relapsed or refractory diffuse large B-cell lymphoma

Population group: only adults (18 years old or older)

Epcoritamab as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

0.16 mg on Day 1, 0.8 mg on Day 8, 48 mg on Days 15 and 22 of the 28-day Cycle 1 and thereafter 48 mg every 1, 2 or 4 weeks, as prescribed for each treatment cycle

Relapsed or refractory follicular lymphoma

Population group: only adults (18 years old or older)

Epcoritamab as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

0.16 mg on Day 1, 0.8 mg on Day 8, 3 mg on Day 15 and 48 mg on Day 22 of the 28-day Cycle 1 and thereafter 48 mg every 1, 2 or 4 weeks, as prescribed for each treatment cycle

Contraindications

Epcoritamab is contraindicated in the following cases:

Pregnancy

Lactation

Live or live-attenuated vaccines

Live organism vaccines

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.